X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN LTD SUN PHARMA/
LUPIN LTD
 
P/E (TTM) x 25.6 19.9 128.8% View Chart
P/BV x 3.7 2.7 138.8% View Chart
Dividend Yield % 0.6 0.9 66.1%  

Financials

 SUN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
LUPIN LTD
Mar-17
SUN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8421,750 48.1%   
Low Rs5721,384 41.4%   
Sales per share (Unadj.) Rs131.6387.4 34.0%  
Earnings per share (Unadj.) Rs32.756.6 57.7%  
Cash flow per share (Unadj.) Rs38.076.8 49.4%  
Dividends per share (Unadj.) Rs3.507.50 46.7%  
Dividend yield (eoy) %0.50.5 103.4%  
Book value per share (Unadj.) Rs152.7298.9 51.1%  
Shares outstanding (eoy) m2,399.26451.58 531.3%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x5.44.0 132.9%   
Avg P/E ratio x21.627.7 78.2%  
P/CF ratio (eoy) x18.620.4 91.3%  
Price / Book Value ratio x4.65.2 88.4%  
Dividend payout %10.713.2 80.8%   
Avg Mkt Cap Rs m1,696,877707,513 239.8%   
No. of employees `00017.516.8 104.3%   
Total wages/salary Rs m49,02328,495 172.0%   
Avg. sales/employee Rs Th18,028.310,418.3 173.0%   
Avg. wages/employee Rs Th2,798.81,697.0 164.9%   
Avg. net profit/employee Rs Th4,479.51,523.0 294.1%   
INCOME DATA
Net Sales Rs m315,784174,943 180.5%  
Other income Rs m6,2321,065 585.1%   
Total revenues Rs m322,016176,008 183.0%   
Gross profit Rs m100,89344,931 224.5%  
Depreciation Rs m12,6489,122 138.6%   
Interest Rs m3,9981,525 262.1%   
Profit before tax Rs m90,47935,349 256.0%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m9983 120.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1169,785 123.8%   
Profit after tax Rs m78,46225,575 306.8%  
Gross profit margin %31.925.7 124.4%  
Effective tax rate %13.427.7 48.4%   
Net profit margin %24.814.6 170.0%  
BALANCE SHEET DATA
Current assets Rs m329,537119,542 275.7%   
Current liabilities Rs m178,87061,206 292.2%   
Net working cap to sales %47.733.3 143.1%  
Current ratio x1.82.0 94.3%  
Inventory Days Days7976 103.9%  
Debtors Days Days8390 92.6%  
Net fixed assets Rs m204,766131,660 155.5%   
Share capital Rs m2,399903 265.6%   
"Free" reserves Rs m363,997134,073 271.5%   
Net worth Rs m366,397134,976 271.5%   
Long term debt Rs m14,36156,478 25.4%   
Total assets Rs m614,102266,073 230.8%  
Interest coverage x23.624.2 97.7%   
Debt to equity ratio x00.4 9.4%  
Sales to assets ratio x0.50.7 78.2%   
Return on assets %13.410.2 131.8%  
Return on equity %21.418.9 113.0%  
Return on capital %24.819.3 128.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11881,885 53.9%   
Fx outflow Rs m24,48421,506 113.8%   
Net fx Rs m19,63460,378 32.5%   
CASH FLOW
From Operations Rs m70,82241,148 172.1%  
From Investments Rs m-42,216-25,287 166.9%  
From Financial Activity Rs m-22,8544,332 -527.6%  
Net Cashflow Rs m6,10720,193 30.2%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PANACEA BIOTECH  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS